Immune Disorders

More than 150 primary immunodeficiency diseases (PIDs) have been identified, a number that does not include acquired immunodeficiencies. Examples of immune disorders include Type 1 diabetes, rheumatoid arthritis, allergies, Crohn’s Disease, and HIV, which infects over 0.5% of the world’s population.

In the reports and subscriptions listed under Research and Markets’ category you will find pipeline assessments of drugs and therapeutics, market forecasts, investment and growth opportunities, and much more. Also explored in-depth is the key role of immune response and pharmaceuticals in transplant medicine, with reviews of clinical trials, market trends and major companies in the areas of lung transplants, liver transplants, transplant inflammation/rejection, etc.

Key players profiled include Abbott Laboratories, Pfizer, Johnson & Johnson, Biogen Idec, Amgen, Bayer AG, Sanofi, and more. Show Less ... more

• Disease & Therapy Review (DTR) Executive Market Summaries

  EURO€ 3,745.00USD$ 3,500.00GBP£ 2,128.00AUD$ 5,095.00JPY¥ 429,472.00SEK 30 202,00CHF 5'027.00CAD$ 4,678.00 Timely Data Resources, Inc, May 2013
  Disease & Therapy Review is meant to be an accurate and efficient executive synopsis of the indications that IPD users look up most frequently Each report includes epidemiology from the IPD (Incidence...

• House Dust Mite Allergy - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 49
  House Dust Mite Allergy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'House Dust Mite Allergy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

• Chronic Plaque Psoriasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 82
  Chronic Plaque Psoriasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Plaque Psoriasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....

• Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Apr 2013 , Pages: 104
  Systemic Sclerosis (Scleroderma) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Cat Allergy - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 35
  Cat Allergy – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Cat Allergy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Lupus Erythematosus - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 238
  Lupus Erythematosus – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Lupus Erythematosus - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Moderate Psoriasis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 64
  Moderate Psoriasis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Moderate Psoriasis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Polio - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 55
  Polio – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Polio - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Non-Small Cell Lung Carcinoma - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 44
  Non-Small Cell Lung Carcinoma – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Non-Small Cell Lung Carcinoma - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...

• Diarrhea - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 123
  Diarrhea – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Diarrhea - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Viral Infections - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 739
  Viral Infections – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Viral Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report...

• Dyskinesia - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 107
  Dyskinesia – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Dyskinesia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 534
  Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2013', provides an overview...

• Ulcerative Colitis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Mar 2013 , Pages: 286
  Ulcerative Colitis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Ulcerative Colitis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Sjogren's Syndrome Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 87
  Sjogren's Syndrome Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Sjogren’s Syndrome Global Clinical Trials Review, H1, 2013" provides data on the Sjogren’s Syndrome clinical...

• Lung Transplantation - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 40
  Lung Transplantation – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Lung Transplantation - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Autoimmune Disorders - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 336
  Autoimmune Disorders – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Autoimmune Disorders - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...

• Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 58
  Hematopoietic Stem Cell Transplantation – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Hematopoietic Stem Cell Transplantation - Pipeline Review, H1 2013', provides an overview of the...

• Osteoarthritis - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 209
  Osteoarthritis – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Osteoarthritis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Systemic Lupus Erythematosus - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 218
  Global Markets Direct's, 'Systemic Lupus Erythematosus - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic...

• Allergies - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 293
  Allergies – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Allergies - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...

• Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Feb 2013 , Pages: 143
  Plaque Psoriasis (Psoriasis Vulgaris) – Pipeline Review, H1 2013 Summary Global Markets Direct’s, 'Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H1 2013', provides an overview of the indication’s...

• Lupus Nephritis Global Clinical Trials Review, H1, 2013

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 GlobalData, Feb 2013 , Pages: 108
  Lupus Nephritis Global Clinical Trials Review, H1, 2013 Summary Our clinical trial report, “Lupus Nephritis Global Clinical Trials Review, H1, 2013" provides data on the Lupus Nephritis clinical trial...

• EpiCast Report: Crohn's Disease Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Jan 2013 , Pages: 56
  Crohn's disease is a form of inflammatory bowel disease (IBD) characterized by recurrent inflammation of all or part of the gastrointestinal tract (CDC, 2011) Globally, the incidence rates for Crohn's...

• Triple Analysis: Lymphoma, Apoptosis and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 3584
  This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lymphoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

• Triple Analysis: Apoptosis, Angiogenesis and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 4334
  This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Angiogenesis and by the compound strategy of Peptides. Each of these three...

• Triple Analysis: Melanoma, Apoptosis and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 3407
  This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

• Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 5570
  This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Peptides. Each...

• Triple Analysis: Lung Cancer, Apoptosis and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 3953
  This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

• Triple Analysis: Pancreatic Cancer, Apoptosis and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 3733
  This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area...

• Triple Analysis: Apoptosis, Antibodies and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 4991
  This triple analysis focuses on cancer drug development strategies by the mechanism/target/effect of Apoptosis and by the two compound strategies of Antibodies and Peptides. Each of these three individual...

• Triple Analysis: Apoptosis, Cancer Vaccines and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 3289
  This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Cancer Vaccines and by the compound strategy of Peptides. Each of these three...

• Triple Analysis: Breast Cancer, Apoptosis and Peptides

  EURO€ 3,450.00USD$ 4,488.00GBP£ 2,903.00AUD$ 4,390.00JPY¥ 443,148.00SEK 29 470,00CHF 4'230.00CAD$ 4,574.00 Bioseeker, Jan 2013 , Pages: 4385
  This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Breast Cancer), one mechanism/target/effect area (Apoptosis) and one compound specific area (Peptides)....

• EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022

  EURO€ 3,071.00USD$ 3,995.00GBP£ 2,584.00AUD$ 3,907.00JPY¥ 394,438.00SEK 26 231,00CHF 3'765.00CAD$ 4,071.00 GlobalData, Dec 2012 , Pages: 76
  EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022 Summary Human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune system, destroying or impairing...

• Inflammation - Pipeline Review, H2 2012

  EURO€ 1,922.00USD$ 2,500.00GBP£ 1,617.00AUD$ 2,445.00JPY¥ 246,832.00SEK 16 415,00CHF 2'356.00CAD$ 2,547.00 Global Markets Direct, Dec 2012 , Pages: 33
  Inflammation – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Inflammation - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides...

• Cedar Pollen Allergy - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Dec 2012 , Pages: 40
  Cedar Pollen Allergy – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Cedar Pollen Allergy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This...

• Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Dec 2012 , Pages: 33
  Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE) – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid...

• Pemphigus Vulgaris - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Dec 2012 , Pages: 32
  Pemphigus Vulgaris – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Pemphigus Vulgaris - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This...

• Food Allergy - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Dec 2012 , Pages: 38
  Food Allergy – Pipeline Review, H2 2012 Summary Global Markets Direct's, 'Food Allergy - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline This report provides...

• Von Hippel-Lindau Syndrome - Pipeline Review, H2 2012

  EURO€ 1,537.00USD$ 2,000.00GBP£ 1,293.00AUD$ 1,956.00JPY¥ 197,466.00SEK 13 132,00CHF 1'885.00CAD$ 2,038.00 Global Markets Direct, Dec 2012 , Pages: 30
  Von Hippel-Lindau Syndrome – Pipeline Review, H2 2012 Summary Global Markets Direct’s, 'Von Hippel-Lindau Syndrome - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic...

• Arcadia Resources Inc.,(KADR) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 51
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Arcadia Resources Inc. (KADR), plus vital industry benchmarks and extensive operating ratios, along with an...

• AtCor Medical Holdings Limited,(AMDHF) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 52
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for AtCor Medical Holdings Limited (AMDHF), plus vital industry benchmarks and extensive operating ratios, along...

• Baxter International Inc,(BAX) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 51
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Baxter International Inc (BAX), plus vital industry benchmarks and extensive operating ratios, along with...

• Atrion Corporation,(ATRI) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 51
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Atrion Corporation (ATRI), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

• Avitar, Inc.,(AVTI) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 47
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Avitar, Inc. (AVTI), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

• ArQule Inc,(ARQL) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 52
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for ArQule Inc (ARQL), plus vital industry benchmarks and extensive operating ratios, along with an analysis of...

• ArthroCare Corp,(ARTC) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 52
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for ArthroCare Corp (ARTC), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

• Assurant Inc,(AIZ) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 51
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Assurant Inc (AIZ), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

• AstraZeneca plc,(AZN) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 52
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for AstraZeneca plc (AZN), plus vital industry benchmarks and extensive operating ratios, along with an analysis...

• Athenahealth Inc,(ATHN) Profile and Financials, plus Health Care Industry Trends Analysis, Operating Ratio and Financial Averages

  EURO€ 76.00USD$ 99.00GBP£ 64.00AUD$ 97.00JPY¥ 9,775.00SEK 650,00CHF 93.00CAD$ 101.00 Plunkett Research Ltd, Dec 2012 , Pages: 51
  Why You Should Buy This Report: A value-packed package of corporate financial analysis, for Athenahealth Inc (ATHN), plus vital industry benchmarks and extensive operating ratios, along with an analysis...